Moleculin Biotech (NASDAQ:MBRX) Upgraded at Maxim Group

Maxim Group upgraded shares of Moleculin Biotech (NASDAQ:MBRX) from a hold rating to a buy rating in a report released on Tuesday morning, MarketBeat reports. Maxim Group currently has $4.00 target price on the stock.

MBRX has been the topic of a number of other research reports. HC Wainwright reiterated a “buy” rating and issued a $8.00 target price on shares of Moleculin Biotech in a report on Monday. StockNews.com started coverage on shares of Moleculin Biotech in a research note on Thursday, March 13th. They issued a “sell” rating on the stock.

Moleculin Biotech Stock Performance

MBRX opened at $1.05 on Tuesday. The stock has a fifty day moving average of $1.30 and a 200-day moving average of $1.99. Moleculin Biotech has a 12-month low of $0.40 and a 12-month high of $6.23.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.